PTLA Stock Price - Portola Pharmaceuticals Inc. Stock Quote (U.S.: Nasdaq) - MarketWatch

Vanguard Health Care Fund Buys Royal Philips NV, Seattle Genetics Inc, Portola Pharmaceuticals Inc, Sells Dentsply Sirona Inc, Edwards Lifesciences Corp, Shanghai Fosun Pharmaceutical (Group) Co

May. 1, 2018 at 3:38 p.m. ET
on GuruFocus.com

Options Traders Expect Huge Moves in Portola (PTLA) Stock

Portola (PTLA) needs investors to pay close attention to the stock based on moves in the options market lately.

May. 1, 2018 at 8:51 a.m. ET
on Zacks.com

3 Small-Cap Biotech Stocks With Big Catalysts in May

Apr. 30, 2018 at 3:01 p.m. ET
on Motley Fool

Key events next week - healthcare

Apr. 27, 2018 at 3:34 p.m. ET
on Seeking Alpha

European advisory group April meeting results

Apr. 27, 2018 at 10:34 a.m. ET
on Seeking Alpha

NHF: Objects In The Rear View Mirror Miss The Storms Ahead?

Mar. 27, 2018 at 4:06 a.m. ET
on Seeking Alpha

Your Daily Pharma Scoop: Clovis Update, Novartis' MS Results, Vericel's SUMMIT Study

Mar. 26, 2018 at 8:00 a.m. ET
on Seeking Alpha

European advisory group thumbs down on Portola's betrixaban, appeal planned

Mar. 23, 2018 at 10:27 a.m. ET
on Seeking Alpha

3 Growth Stocks for Forward-Looking Investors

Mar. 15, 2018 at 10:00 a.m. ET
on Motley Fool

Portola Pharmaceutical's AndexXa Approval Remains Uncertain

Mar. 13, 2018 at 8:00 p.m. ET
on Motley Fool

Your Daily Pharma Scoop: Portola's New Interim Data, Lantheus Announces Promising Data For LMI 1195, Kura Tumbles On Update

Mar. 13, 2018 at 5:27 p.m. ET
on Seeking Alpha

Portola Pharma (PTLA) Announces New Interim Data From Late-Stage Study Of AndexXa - Slideshow

Mar. 13, 2018 at 1:42 p.m. ET
on Seeking Alpha

Portola Pharma announces new interim data from late-stage study of AndexXa; shares down 9%

Mar. 12, 2018 at 1:00 p.m. ET
on Seeking Alpha

Why Portola Pharmaceuticals (PTLA) Could Be Positioned for a Slump

It seems to be a wise decision for investors to drop Portola Pharmaceuticals (PTLA) stock considering its negative estimate revision, price depreciation as well as unfavorable Zacks rank.

Mar. 12, 2018 at 8:58 a.m. ET
on Zacks.com

Key events next week - healthcare (continued #3)

Mar. 9, 2018 at 10:00 a.m. ET
on Seeking Alpha

Portola Pharmaceuticals: What The Latest Developments Regarding AndexXA Entail?

Mar. 5, 2018 at 5:27 a.m. ET
on Seeking Alpha

Portola: Elucidating The Latest Developments On Bevyxxa

Mar. 5, 2018 at 1:35 a.m. ET
on Seeking Alpha

Key events next week - healthcare

Mar. 2, 2018 at 11:03 a.m. ET
on Seeking Alpha

Your Daily Pharma Scoop: Portola Drops On AndexXa Update, NovaVax Top-Line Results, Idera Commences Late-Stage Study With IMO-2125

Mar. 2, 2018 at 8:00 a.m. ET
on Seeking Alpha

U.S. Biotech/Pharma Sector Daily Observations Letter: March 1, 2018

Mar. 2, 2018 at 2:15 a.m. ET
on Seeking Alpha

Factors of Influence in 2018, Key Indicators and Opportunity within Independent Bank Group, Eclipse Resources, Stellus Capital Investment, International Bancshares, Portola Pharmaceuticals, and Revance Therapeutics -- New Research Emphasizes Economic Growth

Factors of Influence in 2018, Key Indicators and Opportunity within Independent Bank Group, Eclipse Resources, Stellus Capital Investment, International Bancshares, Portola Pharmaceuticals, and Revance Therapeutics -- New Research Emphasizes Economic Growth

May. 2, 2018 at 7:51 a.m. ET
on GlobeNewswire

Today's Research Reports on Trending Tickers: Magellan Health and Portola Pharmaceuticals

May. 1, 2018 at 8:32 a.m. ET
on ACCESSWIRE

Portola Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018

Apr. 30, 2018 at 4:31 p.m. ET
on GlobeNewswire

Biotech Stocks' Research Reports Released on Pieris Pharma, Portola Pharma, Protalix BioTherapeutics, and Radius Health

Apr. 27, 2018 at 6:40 a.m. ET
on PR Newswire - PRF

Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr. 25, 2018 at 1:07 p.m. ET
on GlobeNewswire

Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Apr. 4, 2018 at 8:31 a.m. ET
on GlobeNewswire

Today's Research Reports on Trending Tickers: Intrexon and Portola Pharmaceuticals

Apr. 3, 2018 at 8:20 a.m. ET
on ACCESSWIRE

Portola Pharmaceuticals Receives and Plans to Appeal Negative CHMP Opinion Regarding Marketing Authorization for Betrixaban in the European Union

Mar. 23, 2018 at 9:07 a.m. ET
on GlobeNewswire

Global Anticoagulants Industry

Mar. 20, 2018 at 2:19 p.m. ET
on PR Newswire - PRF

Quotidian Technical Highlights on Selected Biotech Stocks -- Portola Pharma, Protalix BioTherapeutics, Radius Health, and Regulus Therapeutics

Mar. 20, 2018 at 6:40 a.m. ET
on PR Newswire - PRF

Today's Research Reports on Trending Tickers: Ligand Pharmaceuticals and Portola Pharmaceuticals

Mar. 19, 2018 at 8:37 a.m. ET
on ACCESSWIRE

US Anticoagulation Therapy Market Industry Analysis, Growth, and Forecast to 2023

Mar. 13, 2018 at 5:16 a.m. ET
on Financeswire

Portola Pharmaceuticals Announces New Interim Results from Ongoing ANNEXA-4 Study of Factor Xa Inhibitor Reversal Agent AndexXa(R) (Andexanet Alfa) in Patients with Life-Threatening Bleeding

Mar. 12, 2018 at 12:12 p.m. ET
on GlobeNewswire

Portola Pharmaceuticals Appoints Biotech Legal Veteran John Moriarty as Executive Vice President and General Counsel

Mar. 12, 2018 at 8:30 a.m. ET
on GlobeNewswire

Today's Research Reports on Stocks to Watch: Spectrum Pharmaceuticals and Portola Pharmaceuticals

Mar. 7, 2018 at 8:11 a.m. ET
on ACCESSWIRE

Portola Pharmaceuticals to Present at Two Upcoming Investor Conferences

Mar. 6, 2018 at 4:05 p.m. ET
on GlobeNewswire

Portola Pharmaceuticals to Host Webcast Event and Conference Call at ACC.18 to Discuss Late-Breaking Oral Presentation Highlighting New Interim Data for Andexanet Alfa

Mar. 5, 2018 at 4:11 p.m. ET
on GlobeNewswire

Today's Research Reports on Trending Tickers: Portola Pharmaceuticals and Valeant Pharmaceuticals

Mar. 1, 2018 at 8:31 a.m. ET
on ACCESSWIRE

Report: Developing Opportunities within Hannon Armstrong Sustainable Infrastructure Capital, Mid-America Apartment Communities, Portola Pharmaceuticals, Molina Healthcare, Trustmark, and Ingredion -- Future Expectations, Projections Moving into 2018

Report: Developing Opportunities within Hannon Armstrong Sustainable Infrastructure Capital, Mid-America Apartment Communities, Portola Pharmaceuticals, Molina Healthcare, Trustmark, and Ingredion -- Future Expectations, Projections Moving into 2018

Mar. 1, 2018 at 7:50 a.m. ET
on GlobeNewswire

Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update

Feb. 28, 2018 at 4:05 p.m. ET
on GlobeNewswire

Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis and other hematologic disorders, and inflammation. Its development-stage portfolio consists of the compounds including Betrixaban, a novel oral once-daily inhibitor of Factor Xa in phase three clinical trials for extended duration prophylaxis, or preventive treatment of a form of thrombosis known as venous thromboembolism, in acute medically ill patients; Andexanet alfa, a recombinant protein designed to reverse anticoagulant activity in patients treated with a Factor Xa inhibitor; and Cerdulatinib, an orally available kinase inhibitor that inhibits spleen tyrosine kinase and janus kinases, enzymes that regulate important signaling pathways. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. (See Full Profile)

Sell
Under
Hold
Over
Buy

Number of Ratings 7 Full Ratings

FDA Risk For Portola Pharma's Thrombosis Treatment Sends Morgan Stanley To Sideline

Mar. 1, 2018 at 11:01 a.m. ET
on Benzinga.com

Benzinga's Top Upgrades, Downgrades For March 1, 2018

Mar. 1, 2018 at 9:47 a.m. ET
on Benzinga.com

How To Trade The JPMorgan Healthcare Conference

Jan. 8, 2018 at 1:19 p.m. ET
on Benzinga.com

Name	Chg %	Market Cap
Biogen Inc.	-2.81%	$57.84B
Bristol-Myers Squibb Co.	-0.10%	$84.18B
Johnson & Johnson	-0.38%	$331.25B
Pfizer Inc.	-0.37%	$207.55B
Sanofi ADR	0.44%	$98.75B

Competitor Data Provided By

Dow	23,930.15	5.17	0.02%
S&P 500	2,629.73	-5.94	-0.23%
Nasdaq	7,088.15	-12.75	-0.18%
GlobalDow	3,023.36	3.32	0.11%
Gold	1,313.60	0.90	0.07%
Oil	68.43	0.00	0.00%

Portola Pharmaceuticals Inc.

$ 35.00

Customize MarketWatch

No Items in Watchlist

No Saved Watchlists

Uh oh

No Recent Tickers

Portola previously said FDA review of AndexXa would run through May 4

Portola Pharma stock halted for pending news; shares were up 3.4% in after-hours trading

Portola Pharma reiterated as buy at Goldman Sachs

Portola's stock on track of biggest one-day gain since going public in May 2013

Portola Pharmaceuticals' stock surges to highest level seen since Sept. 21, 2015

Portola Pharmaceuticals' stock rockets 44% after FDA approves Bevyxxa anticoagulant

Portola Pharmaceuticals started at perform with $28 stock price target at Oppenheimer

Portola Pharmaceuticals stock price target cut to $30 from $33 at Credit Suisse

Portola Pharmaceuticals downgraded to neutral from outperform at Credit Suisse

Portola Pharmaceuticals' stock plunges 30% premarket after trial data disappoints

Stocks

Columns

Authors

Topics

^$ 35.00